These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 2526616)
1. Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet. Koshida R; Vrang L; Gilljam G; Harmenberg J; Oberg B; Wahren B Antimicrob Agents Chemother; 1989 May; 33(5):778-80. PubMed ID: 2526616 [TBL] [Abstract][Full Text] [Related]
2. Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Eriksson BF; Schinazi RF Antimicrob Agents Chemother; 1989 May; 33(5):663-9. PubMed ID: 2546487 [TBL] [Abstract][Full Text] [Related]
3. Reverse transcriptases from human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus (SIVMAC) are susceptible to inhibition by foscarnet and 3'-azido-3'-deoxythymidine triphosphate. Vrang L; Oberg B; Löwer J; Kurth R Antimicrob Agents Chemother; 1988 Nov; 32(11):1733-4. PubMed ID: 2472774 [TBL] [Abstract][Full Text] [Related]
4. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine. Kong XB; Zhu QY; Ruprecht RM; Watanabe KA; Zeidler JM; Gold JW; Polsky B; Armstrong D; Chou TC Antimicrob Agents Chemother; 1991 Oct; 35(10):2003-11. PubMed ID: 1722077 [TBL] [Abstract][Full Text] [Related]
5. Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine. Palmer S; Harmenberg J; Cox S Antimicrob Agents Chemother; 1996 May; 40(5):1285-8. PubMed ID: 8723486 [TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1. Koshida R; Cox S; Harmenberg J; Gilljam G; Wahren B Antimicrob Agents Chemother; 1989 Dec; 33(12):2083-8. PubMed ID: 2533474 [TBL] [Abstract][Full Text] [Related]
7. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Larder BA; Kemp SD; Purifoy DJ Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4803-7. PubMed ID: 2472634 [TBL] [Abstract][Full Text] [Related]
13. Synergism among BIOLF-62, phosphonoformate, and other antiherpetic compounds. Smith KO; Galloway KS; Ogilvie KK; Cheriyan UO Antimicrob Agents Chemother; 1982 Dec; 22(6):1026-30. PubMed ID: 6297382 [TBL] [Abstract][Full Text] [Related]
14. De novo reverse transcription is a crucial event in cell-to-cell transmission of human immunodeficiency virus. Li P; Kuiper LJ; Stephenson AJ; Burrell CJ J Gen Virol; 1992 Apr; 73 ( Pt 4)():955-9. PubMed ID: 1378883 [TBL] [Abstract][Full Text] [Related]
15. Increased efficacy of ganciclovir and foscarnet inhibition of cytomegalovirus replication in vitro by encapsulation in liposomes. Bakker-Woudenberg IA; Lokerse AF; ten Kate M Scand J Infect Dis Suppl; 1990; 74():54-7. PubMed ID: 1965866 [TBL] [Abstract][Full Text] [Related]
16. Comparison of foscarnet and foscarnet esters as anti-influenza virus agents. Strid S; Ekström C; Datema R Chemotherapy; 1989; 35(1):69-76. PubMed ID: 2524368 [TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro. Snoeck R; Lagneaux L; Delforge A; Bron D; Van der Auwera P; Stryckmans P; Balzarini J; De Clercq E Eur J Clin Microbiol Infect Dis; 1990 Aug; 9(8):615-9. PubMed ID: 2170136 [TBL] [Abstract][Full Text] [Related]
18. In vitro inhibition of human herpesvirus-6 by phosphonoformate. Streicher HZ; Hung CL; Ablashi DV; Hellman K; Saxinger C; Fullen J; Salahuddin SZ J Virol Methods; 1988 Sep; 21(1-4):301-4. PubMed ID: 2972736 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of synergy between carbovir and 3'-azido-2',3'-deoxythymidine for inhibition of human immunodeficiency virus type 1. Smith MS; Kessler JA; Rankin CD; Pagano JS; Kurtzberg J; Carter SG Antimicrob Agents Chemother; 1993 Jan; 37(1):144-7. PubMed ID: 8431013 [TBL] [Abstract][Full Text] [Related]
20. In vitro recovery of resistant retrovirus isolates after exposure to phosphonoformate. Muratore O; Varnier OE; Raffanti SP; Schito GC Eur J Clin Microbiol; 1984 Oct; 3(5):447-9. PubMed ID: 6238823 [No Abstract] [Full Text] [Related] [Next] [New Search]